bbhn0 | Knowledge4COVID-19

Property	Value
?:creator	<https://research.tib.eu/covid-19/entity/Delrue%2C_Maxime%3B_Baylatry%2C_Minh_Tam%3B_Joly%2C_Anne-Christine%3B_Corre%2C_Elise%3B_Marjanovic%2C_Zora%3B_El-Khoury-Hanna%2C_Noujoud%3B_F%C3%A9ger%2C_Fr%C3%A9d%C3%A9ric%3B_Suner%2C_Ludovic%3B_Veyradier%2C_Agn%C3%A8s%3B_St%C3%A9panian%2C_Alain%3B_Coppo%2C_Paul>
?:doi	<https://research.tib.eu/covid-19/entity/10.1002/ajh.26022>
?:doi	10.1002/ajh.26022
?:journal	American_journal_of_hematology
?:license	unk
?:pmid	<https://research.tib.eu/covid-19/entity/33068040.0>
?:pmid	33068040.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/347bbhn0_HAS_C0393022_ASSOCIATED_WITH_C0034155>
?:source	Medline
?:title	Efficacy of subcutaneous preemptive rituximab in immune-mediated thrombotic thrombocytopenic purpura: experience from the 12 first cases.
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-10-17

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/347bbhn0>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/347bbhn0>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all